GlassScriptPhysician profile
Summer P Chong
NPI 1770803181
$5,583.10
in general payments reported to CMS, 2019-2025
23 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $231 · 2021: $364 · 2022: $1,092 · 2023: $1,333 · 2024: $1,418 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,747 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.43 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.86 | 2021-2025 | Botox, Rinvoq, Skyrizi |
| Genzyme Corporation | $746.78 | 2020-2025 | |
| Lilly USA, LLC | $551.69 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $388.52 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $361.81 | 2019-2025 | Nemluvio, Dysport |
| E.R. Squibb & Sons, L.L.C. | $358.52 | 2022-2025 | Sotyktu |
| Allergan, INC. | $319.87 | 2020-2022 | |
| Amgen INC. | $238.38 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $226.14 | 2020-2025 | Winlevi, Ilumya |
| Leo Pharma INC. | $225.91 | 2021-2025 | Adbry |
| Incyte Corporation | $213.51 | 2023-2025 | Opzelura |
| Pfizer INC. | $198.73 | 2022-2024 | |
| Ucb, INC. | $136.95 | 2021-2025 | Bimzelx, Cimzia |
| Organon LLC | $84.09 | 2025 | Vtama |
| Janssen Biotech, INC. | $37.49 | 2025 | Simponi Aria, Simponi, Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.27 | 2022-2023 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.50 | 2019-2020 | |
| Biofrontera INC. | $29.97 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Revance Therapeutics, INC. | $24.23 | 2024 | Daxxify |
| Mimedx Group, INC. | $21.45 | 2024 | |
| Arcutis Biotherapeutics, INC. | $18.77 | 2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $18.33 | 2024 | |
| Dermira, INC. | $17.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.